David Charles Fry

Title: David Charles Fry: Innovator in Neuropeptide Research

Introduction

David Charles Fry is a notable inventor based in Langhorne, PA (US). He has made significant contributions to the field of neuropeptide research, holding a total of 5 patents. His work focuses on developing compounds that have potential therapeutic applications for diseases such as obesity and diabetes.

Latest Patents

Fry's latest patents include innovative neuropeptide-2 receptor (Y-2R) agonists. These compounds are described by the formula (I): Y—R—R—X—R—R—R—R—R—R—R—R—R—R—R—R—R—NH (SEQ ID NO: 1). They are designed to be pharmaceutically acceptable salts, derivatives, and fragments, with specific substituents detailed in the specification. The pharmaceutical compositions containing these compounds are particularly useful for treating obesity and diabetes.

Career Highlights

David Fry is currently associated with Hoffmann-La Roche Inc., where he continues to advance his research in neuropeptide-2 receptor agonists. His work has garnered attention for its potential impact on public health, particularly in addressing metabolic disorders.

Collaborations

Fry collaborates with talented individuals such as Waleed Danho and Wajiha Khan. Their combined expertise contributes to the innovative research being conducted at Hoffmann-La Roche Inc.

Conclusion

David Charles Fry is a prominent inventor whose work in neuropeptide research holds promise for the treatment of significant health issues. His contributions through patents and collaborations continue to shape the future of therapeutic developments.